These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29070272)

  • 21. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.
    De Jong HJI; Voorham J; Scadding GK; Bachert C; Canonica GW; Smith P; Wahn U; Ryan D; Castillo JA; Carter VA; Murray RB; Price DB
    World Allergy Organ J; 2020 Dec; 13(12):100490. PubMed ID: 33376573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal spray medications for maintenance therapy of allergic rhinitis.
    Berger WE; Meltzer EO
    Am J Rhinol Allergy; 2015; 29(4):273-82. PubMed ID: 26132312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review.
    Tantilipikorn P; Kirtsreesakul V; Bunnag C; Vangveeravong M; Thanaviratananich S; Chusakul S
    J Asthma Allergy; 2024; 17():667-679. PubMed ID: 39045291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
    Klimek L; Demoly P; Price D
    Expert Rev Clin Pharmacol; 2016; 9(5):705-14. PubMed ID: 26839083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis.
    Klimek L; Mullol J; Hellings P; Gevaert P; Mösges R; Fokkens W
    Expert Opin Pharmacother; 2016; 17(5):657-69. PubMed ID: 26800187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber.
    Bousquet J; Meltzer EO; Couroux P; Koltun A; Kopietz F; Munzel U; Kuhl HC; Nguyen DT; Salapatek AM; Price D
    J Allergy Clin Immunol Pract; 2018; 6(5):1726-1732.e6. PubMed ID: 29425904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey.
    Canonica GW; Klimek L; Acaster S; Dollner R; Kaulsay R; Lo SH; Price DB; Scadding GK; Valovirta E; Zieglmayer P
    Curr Med Res Opin; 2021 Jul; 37(7):1259-1272. PubMed ID: 33840316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis.
    Zhong Z; Xun Y; Shi X; Guan B; Wang M
    Eur Arch Otorhinolaryngol; 2022 May; 279(5):2457-2464. PubMed ID: 34415405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy.
    Klimek L; Poletti SC; Sperl A; Spielhaupter M; Bardenhewer C; Mullol J; Hörmann K; Hummel T
    Int Forum Allergy Rhinol; 2017 Mar; 7(3):287-292. PubMed ID: 27888645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells.
    Berger WE; Bachert C; Allara R; Koltun A; Kopietz F; Maus JG; D'Addio AD
    J Asthma Allergy; 2020; 13():187-192. PubMed ID: 32547111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option.
    Bjermer L; Westman M; Holmström M; Wickman MC
    Allergy Asthma Clin Immunol; 2019; 15():24. PubMed ID: 31015846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.
    Roca-Ferrer J; Pujols L; Pérez-González M; Alobid I; Callejas B; Vicens-Artés S; Fuentes M; Valero A; Picado C; Castor D; Nguyen D; Mullol J
    Allergy Asthma Clin Immunol; 2018; 14():86. PubMed ID: 30574167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
    Scadding G; Bousquet J; Bachert C; Fokkens WJ; Hellings PW; Prokopakis E; Pfaar O; Price D
    Rhinology; 2019 Feb; 57(1):49-56. PubMed ID: 30052697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.
    Bachert C; Bousquet J; Hellings P
    Clin Transl Allergy; 2018; 8():25. PubMed ID: 29983907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R.
    Ekstedt S; Kumlien Georén S; Cardell LO
    Allergy Asthma Clin Immunol; 2020; 16():45. PubMed ID: 32514276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over diagnosis of persistent allergic rhinitis in perennial allergic rhinitis patients: a nationwide study in Mexico.
    Larenas-Linnemann D; Dinger H; Shah-Hosseini K; Michels A; Mösges R;
    Am J Rhinol Allergy; 2013; 27(6):495-501. PubMed ID: 24274225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers.
    Qi W; Liu Y; Xue W; Li K; Gorski JC; Liu M; Yan T; Nguyen DT; Ramalingam RK
    J Asthma Allergy; 2023; 16():667-677. PubMed ID: 37409000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
    J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of MP-AzeFlu compared to monotherapy on COX-2, PGE
    Vicens-Artes S; Roca-Ferrer J; Tubita V; Fuentes M; Alobid I; Valero A; Kopietz F; Nguyen D; Mullol J
    Immun Inflamm Dis; 2023 Jan; 11(1):e709. PubMed ID: 36705401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
    Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.